{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:46:07Z","timestamp":1791963967740,"version":"4.3.4"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:p>\n                    Serous carcinomas are copy-number-high (p53-abnormal) endometrial carcinomas with adverse outcomes. We aimed to assess the prognostic value of classic morphologic features in these tumors. Treatment-naive uterine serous carcinomas diagnosed from 1995 to 2022 were identified, and clinical-pathologic features were evaluated. The median age was 71 (52 to 95) years. Of 138 tumors, most (87 [63%]) were myoinvasive, and 51 (37%) were endometrium-confined, including 11 (21.6%) with only intraepithelial growth and 40 (78.4%) with stromal invasion within polyps and\/or background endometrium. Predominant growth pattern was papillary in 63 tumors (45.6%), glandular in 60 (43.5%), and solid in 15 (10.9%). Lymphovascular invasion (LVI) was present in 49 (35.5%) cases, with nodal micro\/macrometastases in 25\/106 (23.6%) and isolated tumor cells in 3\/106 (2.8%). Of 126 patients with follow-up (median: 38\u00a0mo, 0.9 to 230.7), 49 (38.9%) experienced recurrences and 27 (21.4%) died of disease. Both recurrence-free and disease-specific survival were associated with T category of pTNM staging, FIGO stage, endometrial stromal invasion, myoinvasion, margin status, cervical, lower uterine segment, and uterine serosal involvement (all\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt;0.0001), LVI (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u22640.002), predominant growth pattern, surrounding intraepithelial growth, and multinucleated tumor cells (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u22640.01). Patients with only intraepithelial growth experienced no recurrence or cancer-related death. LVI was associated with decreased recurrence-free (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt;0.0001) and disease-specific (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt;0.001) survival regardless of extent. T category (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.0049) and uterine serosal involvement (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.0514) were independent predictors of recurrence-free survival, with T category (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.03) also predicting disease-specific survival. The presence of only intraepithelial growth portends a favorable prognosis in serous carcinoma, whereas the clinical significance of the extent of LVI is limited.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000002603","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:00:14Z","timestamp":1787720414000},"page":"1352-1361","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathologic Analysis of 138 Uterine Serous Carcinomas"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1572-8200","authenticated-orcid":false,"given":"Maximilian","family":"Lennartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Hsu Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle M.","family":"Devins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6125-5865","authenticated-orcid":false,"given":"Gulisa","family":"Turashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"R1-20261014","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"R2-20261014","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"R3-20261014","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/GCO.0b013e328334d8a3","article-title":"Uterine papillary serous carcinoma: epidemiology, pathogenesis and management","volume":"22","author":"Fader","year":"2010","journal-title":"Curr Opin Obstet Gynecol"},{"key":"R4-20261014","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br J Cancer"},{"key":"R5-20261014","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/GRF.0b013e318218c755","article-title":"Uterine papillary serous carcinoma","volume":"54","author":"Moore","year":"2011","journal-title":"Clin Obstet Gynecol"},{"key":"R6-20261014","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/modpathol.3800271","article-title":"Minimal uterine serous carcinoma: a clinicopathological study of 40 cases","volume":"18","author":"Hui","year":"2005","journal-title":"Mod Pathol"},{"key":"R7-20261014","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/PAS.0b013e318202772e","article-title":"A proposed model for endometrial serous carcinogenesis","volume":"35","author":"Zheng","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"R8-20261014","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/106689690401200302","article-title":"Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features","volume":"12","author":"Zheng","year":"2004","journal-title":"Int J Surg Pathol"},{"key":"R10-20261014","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/00000478-200006000-00004","article-title":"Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation","volume":"24","author":"Wheeler","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"R11-20261014","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00004347-200107000-00002","article-title":"Early uterine serous carcinoma: clonal origin of extrauterine disease","volume":"20","author":"Baergen","year":"2001","journal-title":"Int J Gynecol Pathol"},{"key":"R12-20261014","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/cncr.24247","article-title":"Platinum\/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma","volume":"115","author":"Fader","year":"2009","journal-title":"Cancer"},{"key":"R13-20261014","doi-asserted-by":"crossref","first-page":"284","DOI":"10.6004\/jnccn.2025.0038","article-title":"NCCN Guidelines\u00ae insights: uterine neoplasms, version 3.2025","volume":"23","author":"Abu-Rustum","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"R14-20261014","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2017.07.119","article-title":"Extent of lymphovascular space invasion may predict lymph node metastasis in uterine serous carcinoma","volume":"147","author":"Qian","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R15-20261014","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/PGP.0000000000000113","article-title":"Significance of lymphovascular space invasion in uterine serous carcinoma: what matters more; extent or presence?","volume":"34","author":"Winer","year":"2015","journal-title":"Int J Gynecol Pathol"},{"key":"R16-20261014","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.ejca.2015.05.015","article-title":"Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer\u2014a pooled analysis of PORTEC 1 and 2 trials","volume":"51","author":"Bosse","year":"2015","journal-title":"Eur J Cancer"},{"key":"R17-20261014","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0046-8177(85)80210-0","article-title":"Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases","volume":"16","author":"Ulbright","year":"1985","journal-title":"Hum Pathol"},{"key":"R18-20261014","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/PAS.0b013e31818a01bf","article-title":"Vascular pseudoinvasion in laparoscopic hysterectomy specimens for endometrial carcinoma: a grossing artifact?","volume":"33","author":"Kitahara","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"suppl 2","key":"R19-20261014","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ijgo.12612","article-title":"Cancer of the corpus uteri","volume":"143","author":"Amant","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"issue":"suppl 1","key":"R20-20261014","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/PGP.0000000000000491","article-title":"High-grade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations","volume":"38","author":"Murali","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"R21-20261014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2021.09.001","article-title":"Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationship","volume":"118","author":"Assem","year":"2021","journal-title":"Hum Pathol"},{"key":"R23-20261014","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"R24-20261014","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl 1","key":"R26-20261014","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1097\/PGP.0000000000000524","article-title":"Pathologic prognostic factors in endometrial carcinoma (other than tumor type and grade)","volume":"38","author":"Singh","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"R27-20261014","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/PGP.0000000000000806","article-title":"Defining substantial lymphovascular space invasion in endometrial cancer","volume":"41","author":"Peters","year":"2022","journal-title":"Int J Gynecol Pathol"},{"key":"R28-20261014","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/his.15272","article-title":"Practical guidance for assessing and reporting lymphovascular space invasion (LVSI) in endometrial carcinoma","volume":"86","author":"Peters","year":"2025","journal-title":"Histopathology"},{"key":"R29-20261014","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5858\/arpa.2022-0280-RA","article-title":"Practical updates and diagnostic challenges in endometrial carcinoma","volume":"148","author":"Turashvili","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"R30-20261014","author":"Turashvili"},{"key":"R31-20261014","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ygyno.2009.07.030","article-title":"An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)","volume":"115","author":"Fader","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R32-20261014","first-page":"70","article-title":"Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases","volume":"3","author":"Fadare","year":"2013","journal-title":"Am J Cancer Res"},{"key":"R33-20261014","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/PAS.0000000000001401","article-title":"Mesonephric-like carcinoma of the endometrium: a subset of endometrial carcinoma with an aggressive behavior","volume":"44","author":"Euscher","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R34-20261014","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/PAS.0000000000002382","article-title":"Primary endometrial gastric (gastrointestinal)-type mucinous adenocarcinoma: a detailed clinicopathologic and molecular analysis of 27 cases","volume":"49","author":"Kaur","year":"2025","journal-title":"Am J Surg Pathol"},{"key":"R35-20261014","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/s41379-019-0341-6","article-title":"Endometrial tumors with yolk sac tumor-like morphologic patterns or immunophenotypes: an expanded appraisal","volume":"32","author":"Fadare","year":"2019","journal-title":"Mod Pathol"},{"key":"R36-20261014","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/PAS.0000000000002230","article-title":"Yolk Sac differentiation in endometrial carcinoma: incidence and clinicopathologic features of somatically derived yolk sac tumors versus carcinomas with nonspecific immunoexpression of yolk sac markers","volume":"48","author":"Mills","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"R37-20261014","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/PAS.0000000000002165","article-title":"Specific pathology features enrich selection of endometrial carcinomas for POLE testing","volume":"48","author":"Keyhanian","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"R38-20261014","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/PAS.0000000000002503","article-title":"A deeper dive into POLE\u2014mutated endometrial carcinomas: the contributions and consequences of tumor mutational burden","volume":"50","author":"Vemuri","year":"2026","journal-title":"Am J Surg Pathol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:00:11Z","timestamp":1791961211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002603"}},"subtitle":["Morphology Revisited"],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002603","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"2026-05-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}